Key result
Pemafibrate XR cuts fasting triglycerides by ~41%, proving non-inferior to the IR formulation.
Why the study?
To compare the efficacy, safety, and pharmacokinetics of once-daily pemafibrate extended-release tablets with twice-daily immediate-release tablets in patients with hypertriglyceridemia.
Does pemafibrate extended-release (0.4 or 0.8 mg/day) reduce fasting serum triglycerides non-inferiorly to pemafibrate immediate-release (0.2 mg/day) in patients with hypertriglyceridemia?
RCT (n=60)
Single-blind
Dynamic allocation
Yes
Does pemafibrate extended-release (0.4 or 0.8 mg/day) reduce fasting serum triglycerides non-inferiorly to pemafibrate immediate-release (0.2 mg/day) in patients with hypertriglyceridemia?
Once-daily extended-release pemafibrate (0.4 mg/day) provides comparable triglyceride-lowering efficacy and safety to twice-daily immediate-release pemafibrate (0.2 mg/day) in patients with hypertriglyceridemia.
Answers are grounded in this paper and cite their sources.
Supports once-daily dosing in hypertriglyceridemia; confirms non-inferiority of extended-release pemafibrate to immediate-release.
AIMS: Efficacy, safety, and pharmacokinetics of the selective PPARα modulator pemafibrate as once-daily extended-release (XR) tablets were compared with those of twice-daily immediate-release (IR) tablets in patients with hypertriglyceridemia. METHODS: A multicenter, randomized, single-blind, active-controlled crossover, phase 2 clinical pharmacology study was performed in patients with hypertriglyceridemia. Patients were randomly assigned to IR 0.2 mg/day, XR 0.4 mg/day, or XR 0.8 mg/day before/after meals (fasted/fed) and treated for a total of eight weeks. The primary endpoint was percentage change in fasting serum triglycerides (TG). RESULTS: were longer for XR than for IR. Adverse events showed no major inter-group differences: 12.5% (5/40 patients) for IR 0.2, 17.5% (7/40) for XR 0.4, and 20.0% (8/40) for XR 0.8 mg/day. CONCLUSIONS: In patients with hypertriglyceridemia, XR substantially lowered TG at all doses, with maximum effectiveness at 0.4 mg/day, the dose approved in Japan, to a level comparable to IR 0.2 mg/day. There were no safety concerns up to 0.8 mg/day.
No takes yet. Share an insight, caveat, or question.
Yamashita et al. (2024) conducted an RCT in Hypertriglyceridemia (n=60). Pemafibrate extended-release (XR) vs. Pemafibrate immediate-release (IR) 0.2 mg/day was evaluated on Percentage change in fasting serum triglycerides from baseline to 4 weeks (Difference 2.5%, 95% CI -1.5, 6.5). In patients with hypertriglyceridemia, pemafibrate extended-release /day reduced fasting serum triglycerides by 41.1%, demonstrating non-inferiority to the immediate-release /day formulation.
Synapse has enriched 10 related papers. Consider them for comparative context: